If the EMA also stops releasing data on old trials, everybody will be kept even more in the dark, according to an editorial posted by bmj.com on May 28.
Despite some setbacks, great strides have been made in the past three years towards clinical trial transparency, but a great deal of information still remains hidden from policymakers, clinicians, and patients, and if the European Medicines Agency (EMA) also stops releasing data on old trials, everybody will be kept even more in the dark, according to an editorial posted by bmj.com on May 28.
EMA’s management board is due to meet on June 12 to finalize the policy, and some observers have expressed concern over recent weeks that the Agency has decided to backtrack on its decision for public access to clinical trial data.
On the plus side, even with a “watered down policy”, EMA will be making visible vast quantities of new regulatory information about randomized controlled trials of drugs and other types of interventional or observational clinical research methodologies, noted the BMJ’s Head of Research, Trish Groves, and European Research Editor, Wim Weber.
However, if the new European policies for proactive disclosure close the EMA window that has been allowing ad hoc retroactive access to older clinical study reports and data, then decision-makers will be even less well informed when making decisions about current treatments, they noted.
“That is why AllTrials continues to campaign for all clinical trials to be registered and all results reported. The research, advocacy, haggling, and politics must go on,” the authors wrote.
Read the full release here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.